Monophosphoryl lipid A attenuates myocardial stunning in dogs: role of ATP-sensitive potassium channels
- PMID: 9676720
- DOI: 10.1097/00005344-199807000-00008
Monophosphoryl lipid A attenuates myocardial stunning in dogs: role of ATP-sensitive potassium channels
Abstract
Results of previous studies indicate that monophosphoryl lipid A (MLA) reduces myocardial infarct size when administered 24 but not 1 h before a prolonged period of regional ischemia in dogs and rabbits. This cardioprotective effect of MLA could be reversed by the administration of the adenosine triphosphate (ATP)-sensitive potassium channel (K(ATP)) blockers, glibenclamide, or 5-hydroxydecanoate. MLA also was shown to attenuate myocardial stunning in dogs; however, its mechanism in this model remains unknown. Therefore the major aim of our study was to determine the dose-related effect of MLA to enhance contractile function in stunned myocardium and to determine the role of the K(ATP) channel in mediating its cardioprotective effect. To produce myocardial stunning, barbital-anesthetized dogs were subjected to five cycles of 5 min of left anterior descending (LAD) coronary artery occlusion interspersed with 10 min of reperfusion and finally followed by 2 h of reperfusion. Regional segment shortening (%SS) was determined by sonomicrometers implanted in the subendocardium of the ischemic region. Single intravenous doses of MLA in the range of 10-35 microg/kg given 24 h before ischemia resulted in an improvement in %SS over a 2-h reperfusion period. Similar to results obtained in the canine and rabbit infarct models, cardioprotection against stunning with MLA appears to require activation of K(ATP) channels during ischemia, because glibenclamide (50 microg/kg, 15 min before ischemia) completely blocked the effect of MLA to improve regional %SS during reperfusion. Cardioprotective doses of MLA were without effect on systemic hemodynamics, blood gases, and pH throughout the experiment. No treatment-related effects on regional myocardial blood flow were observed during ischemia or reperfusion. These results suggest that MLA improves %SS at doses of 10-35 microg/kg by an ATP-sensitive potassium channel-dependent process, and that MLA may mimic the antistunning effects observed during the second window of ischemic preconditioning.
Similar articles
-
Myocardial ischemia/reperfusion protection using monophosphoryl lipid A is abrogated by the ATP-sensitive potassium channel blocker, glibenclamide.Cardiovasc Res. 1996 Dec;32(6):1071-80. doi: 10.1016/s0008-6363(96)00154-x. Cardiovasc Res. 1996. PMID: 9015409
-
Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning.Circulation. 1992 Jul;86(1):311-9. doi: 10.1161/01.cir.86.1.311. Circulation. 1992. PMID: 1301066
-
Sevoflurane protects stunned myocardium through activation of mitochondrial ATP-sensitive potassium channels.Anesth Analg. 2001 May;92(5):1139-45. doi: 10.1097/00000539-200105000-00012. Anesth Analg. 2001. PMID: 11323336
-
Pharmacologic myocardial preconditioning with monophosphoryl lipid A (MLA) reduces infarct size and stunning in dogs and rabbits.Ann N Y Acad Sci. 1996 Sep 30;793:386-99. doi: 10.1111/j.1749-6632.1996.tb33530.x. Ann N Y Acad Sci. 1996. PMID: 8906181 Review.
-
ATP-sensitive K+ channel openers: old drugs with new clinical benefits for the heart.Curr Vasc Pharmacol. 2003 Oct;1(3):251-8. doi: 10.2174/1570161033476646. Curr Vasc Pharmacol. 2003. PMID: 15320472 Review.
Cited by
-
Pretreatment with a novel Toll-like receptor 4 agonist attenuates renal ischemia-reperfusion injury.Am J Physiol Renal Physiol. 2023 May 1;324(5):F472-F482. doi: 10.1152/ajprenal.00248.2022. Epub 2023 Mar 30. Am J Physiol Renal Physiol. 2023. PMID: 36995924 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources